SC Methylnaltrexone (MNTX)

DRUG4 trials

Sponsors

Bausch Health Americas, Inc.

Conditions

Healthy AdultsHealthy SubjectsLiver DysfunctionTerminal Illness

Phase 1

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

CompletedNCT01367535

Bausch Health Americas, Inc.Healthy Adults

Start: 2006-03-31End: 2006-08-31Updated: 2019-11-27

Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose

CompletedNCT01367496

Bausch Health Americas, Inc.Healthy Subjects

Start: 2002-06-30End: 2002-08-31Updated: 2019-11-27

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function

CompletedNCT01367522

Bausch Health Americas, Inc.Liver Dysfunction

Start: 2004-03-31End: 2004-07-31Updated: 2019-11-27

Phase 3

Open-Label Treatment Extension of Protocol MNTX 301

CompletedNCT01367600

Bausch Health Americas, Inc.Terminal Illness

Start: 2003-02-28End: 2005-02-28Updated: 2019-11-27